JP2018510637A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510637A5 JP2018510637A5 JP2017549757A JP2017549757A JP2018510637A5 JP 2018510637 A5 JP2018510637 A5 JP 2018510637A5 JP 2017549757 A JP2017549757 A JP 2017549757A JP 2017549757 A JP2017549757 A JP 2017549757A JP 2018510637 A5 JP2018510637 A5 JP 2018510637A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- polypeptide
- protein complex
- interaction pair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 111
- 230000003993 interaction Effects 0.000 claims description 80
- 102000004169 proteins and genes Human genes 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 75
- 229920001184 polypeptide Polymers 0.000 claims description 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 62
- 230000004927 fusion Effects 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 102000016970 Follistatin Human genes 0.000 claims description 10
- 108010014612 Follistatin Proteins 0.000 claims description 10
- 108010059616 Activins Proteins 0.000 claims description 9
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 9
- 239000000488 activin Substances 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 4
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 4
- 108010023079 activin B Proteins 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 108010023082 activin A Proteins 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 claims description 2
- 238000000423 cell based assay Methods 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 101000803329 Homo sapiens WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 Proteins 0.000 claims 18
- 108010056852 Myostatin Proteins 0.000 claims 4
- 101710087237 Whey acidic protein Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000710 homodimer Substances 0.000 claims 1
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021037388A JP2021097697A (ja) | 2015-03-26 | 2021-03-09 | フォリスタチン関連融合タンパク質およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562138886P | 2015-03-26 | 2015-03-26 | |
| US62/138,886 | 2015-03-26 | ||
| PCT/US2016/024368 WO2016154601A1 (en) | 2015-03-26 | 2016-03-25 | Follistatin-related fusion proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037388A Division JP2021097697A (ja) | 2015-03-26 | 2021-03-09 | フォリスタチン関連融合タンパク質およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018510637A JP2018510637A (ja) | 2018-04-19 |
| JP2018510637A5 true JP2018510637A5 (enExample) | 2019-05-09 |
Family
ID=56978700
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549757A Pending JP2018510637A (ja) | 2015-03-26 | 2016-03-25 | フォリスタチン関連融合タンパク質およびその使用 |
| JP2021037388A Pending JP2021097697A (ja) | 2015-03-26 | 2021-03-09 | フォリスタチン関連融合タンパク質およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037388A Pending JP2021097697A (ja) | 2015-03-26 | 2021-03-09 | フォリスタチン関連融合タンパク質およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9975934B2 (enExample) |
| EP (1) | EP3274457A4 (enExample) |
| JP (2) | JP2018510637A (enExample) |
| KR (1) | KR20170129233A (enExample) |
| CN (1) | CN107636154A (enExample) |
| AU (2) | AU2016238254B2 (enExample) |
| CA (1) | CA2980757A1 (enExample) |
| WO (1) | WO2016154601A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102131822A (zh) | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| EA202090632A1 (ru) * | 2014-06-04 | 2020-07-31 | Акселерон Фарма Инк. | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов |
| EP3274457A4 (en) * | 2015-03-26 | 2018-08-08 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| US10358476B2 (en) | 2015-04-06 | 2019-07-23 | Acceleron Pharma Inc. | Single arm type I and type II receptor fusion proteins and uses thereof |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| WO2017177013A1 (en) | 2016-04-06 | 2017-10-12 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| AU2017338915B2 (en) * | 2016-10-05 | 2024-11-21 | Acceleron Pharma Inc. | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof |
| CA3039573A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
| CN110846400A (zh) * | 2019-10-30 | 2020-02-28 | 吉林大学 | 人外周血循环FST mRNA检测试剂盒及其用途 |
| WO2022067028A1 (en) * | 2020-09-25 | 2022-03-31 | Bigelow Laboratory For Ocean Sciences | Engineered perkinsus marinus cells |
| KR20230118573A (ko) * | 2020-11-11 | 2023-08-11 | 에이치큐 한 | 액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도 |
| US20220380422A1 (en) * | 2021-05-28 | 2022-12-01 | Lirsamax, Inc. | Method for treating muscle atrophy and/or obesity and composition for use in said method |
| CN119343367A (zh) * | 2022-06-15 | 2025-01-21 | Ucb生物制药有限责任公司 | 卵泡抑素融合蛋白 |
| US20260049114A1 (en) * | 2022-06-15 | 2026-02-19 | UCB Biopharma SRL | Fusion protein for the prevention, treatment or amelioration of kidney diseases |
| CN116358954B (zh) * | 2023-02-22 | 2024-08-09 | 深圳市昭蓝生物科技有限公司 | 复合质控品及其制备方法和产前筛查试剂盒 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041538A (en) | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
| US5182375A (en) | 1987-08-28 | 1993-01-26 | The Salk Institute For Biological Studies | DNA encoding follistatin |
| JP3670276B2 (ja) | 1991-02-08 | 2005-07-13 | プロゲニクス・ファーマスーティカルズ、インコーポレイテッド | ＣＤ４― ガンマ・２キメラ及びＣＤ４ ― ＩｇＧ２・キメラ |
| CA2144081C (en) | 1992-09-16 | 2004-11-30 | Filip Roos | Protection against liver damage by hgf |
| JPH09503673A (ja) | 1993-10-14 | 1997-04-15 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | ニューロン細胞の誘導および維持法 |
| US6686198B1 (en) | 1993-10-14 | 2004-02-03 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
| US5545616A (en) | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| GB2306481A (en) | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| AU777783B2 (en) | 1999-04-19 | 2004-10-28 | Kyowa Hakko Kogyo Co. Ltd. | Proliferation inhibitor for androgen-independent tumor |
| WO2001009368A1 (en) | 1999-07-30 | 2001-02-08 | The General Hospital Corporation | Follistatin antagonists |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| CN1929734A (zh) * | 2002-02-21 | 2007-03-14 | 惠氏公司 | 含卵泡抑素区的蛋白质 |
| CN1993048A (zh) | 2002-02-21 | 2007-07-04 | 惠氏公司 | 包含促滤泡素抑制素结构域的蛋白质 |
| EP1572909A4 (en) * | 2002-02-21 | 2007-06-06 | Wyeth Corp | PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN |
| BR0307871A (pt) | 2002-02-21 | 2005-04-12 | Wyeth Corp | Proteìnas contendo domìnio de folistatina |
| EP1646400B1 (en) | 2003-03-21 | 2010-07-21 | Celldex Therapeutics Limited | Treatment of allergic diseases using a modulator of the notch signaling pathway |
| US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| RU2322261C2 (ru) | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| WO2005025601A1 (en) | 2003-09-15 | 2005-03-24 | Monash University | Follistatin isoforms and uses thereof |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| WO2005032578A1 (en) | 2003-10-06 | 2005-04-14 | Monash University | Therapeutic method |
| JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| AU2005272646A1 (en) | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| PL2407486T3 (pl) | 2005-08-19 | 2018-05-30 | Wyeth Llc | Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8 |
| WO2007067616A2 (en) | 2005-12-06 | 2007-06-14 | Amgen Inc | Uses of myostatin antagonists |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| WO2008060139A1 (en) | 2006-11-17 | 2008-05-22 | Erasmus University Medical Center Rotterdam | Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein |
| EP2097095B1 (en) | 2006-11-29 | 2016-01-27 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| CN104524548A (zh) | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| JP6157046B2 (ja) * | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| CN102131822A (zh) | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| EP3202459B1 (en) | 2009-09-09 | 2021-04-14 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content |
| JP2013512674A (ja) * | 2009-12-02 | 2013-04-18 | アクセルロン ファーマ， インコーポレイテッド | Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法 |
| KR101603001B1 (ko) | 2010-08-25 | 2016-03-11 | 에프. 호프만-라 로슈 아게 | Il-18r1에 대한 항체 및 그의 용도 |
| ES2758994T3 (es) * | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9248181B2 (en) * | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| CN103387616A (zh) * | 2012-05-10 | 2013-11-13 | 江苏省弗泰生物科技有限公司 | EPO变体与Fc融合蛋白 |
| EP2844271B1 (en) | 2012-05-17 | 2018-02-28 | Paranta Biosciences Limited | Use of follistatin or of an activin inhibitor for preventing or treating tissue graft dysfunction |
| US9943574B2 (en) | 2012-06-27 | 2018-04-17 | Arthrogen B.V. | Combination for treating an inflammatory disorder |
| ES2715710T3 (es) * | 2013-01-25 | 2019-06-05 | Shire Human Genetic Therapies | Folistatina en el tratamiento de la distrofía muscular de Duchenne |
| WO2014187807A1 (en) * | 2013-05-21 | 2014-11-27 | Arcarios B.V. | Follistatin derivatives |
| CN103554268B (zh) * | 2013-11-01 | 2015-04-01 | 广州联康生物科技有限公司 | 长效重组促卵泡激素及其应用 |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| EA202090632A1 (ru) * | 2014-06-04 | 2020-07-31 | Акселерон Фарма Инк. | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов |
| CN104293834B (zh) * | 2014-10-11 | 2018-03-23 | 上海兴迪金生物技术有限公司 | GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法 |
| EP3274457A4 (en) * | 2015-03-26 | 2018-08-08 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
-
2016
- 2016-03-25 EP EP16769819.0A patent/EP3274457A4/en active Pending
- 2016-03-25 CA CA2980757A patent/CA2980757A1/en active Pending
- 2016-03-25 AU AU2016238254A patent/AU2016238254B2/en not_active Ceased
- 2016-03-25 KR KR1020177029984A patent/KR20170129233A/ko not_active Abandoned
- 2016-03-25 JP JP2017549757A patent/JP2018510637A/ja active Pending
- 2016-03-25 WO PCT/US2016/024368 patent/WO2016154601A1/en not_active Ceased
- 2016-03-25 US US15/081,629 patent/US9975934B2/en active Active
- 2016-03-25 CN CN201680030289.9A patent/CN107636154A/zh active Pending
-
2018
- 2018-04-19 US US15/957,026 patent/US11001614B2/en active Active
-
2021
- 2021-03-09 JP JP2021037388A patent/JP2021097697A/ja active Pending
-
2022
- 2022-04-14 AU AU2022202514A patent/AU2022202514A1/en not_active Abandoned